Pseudomyogenic Hemangioendothelioma Arising in the Maxillary Sinus, an Uncommon and Misdiagnosed Tumor: A Case Report.

Ear Nose Throat JMar 20, 2024 (epub)

Hafsa El Ouazzani, Olaya Hamidi, Alain Habimana et al.

✦ AI-curated · Sources linked

Case in brief

The report describes pseudomyogenic hemangioendothelioma (PMHE), a vascular neoplasm with intermediate-to-low-grade malignant potential, arising in the maxillary sinus. PMHE can show varied histological patterns and resemble vascular or myoid tumors and carcinomas, making pathological distinction challenging. The authors present the lesion as a diagnostic case and discuss its differential diagnoses; the abstract does not provide further clinical findings, investigations, or outcome.

What made this case unusual

The reported tumor arose in the maxillary sinus, an unusual head-and-neck site for PMHE; the authors describe it as the first such case to their knowledge.

Diagnostic / clinical pearl

Because PMHE has variable histology and can mimic several tumor types, include it in the differential diagnosis of a maxillary sinus neoplasm and distinguish it carefully on pathological assessment.

Source

Published in Ear Nose Throat J. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pathology (Anatomic & Clinical)

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.